Evolution of Mutational Landscape and Tumor Immune-Microenvironment in Liver Oligo-Metastatic Colorectal Cancer.
KRAS
SMAD4
colorectal cancer
liver metastases
next generation sequencing
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
21 Oct 2020
21 Oct 2020
Historique:
received:
29
09
2020
revised:
14
10
2020
accepted:
18
10
2020
entrez:
24
10
2020
pubmed:
25
10
2020
medline:
25
10
2020
Statut:
epublish
Résumé
Genetic dynamics underlying cancer progression are largely unknown and several genes involved in highly prevalent illnesses (e.g., hypertension, obesity, and diabetes) strongly concur to cancer phenotype heterogeneity. To study genotype-phenotype relationships contributing to the mutational evolution of colorectal cancer (CRC) with a focus on liver metastases, we performed genome profiling on tumor tissues of CRC patients with liver metastatic disease and no co-morbidities. We studied 523 cancer-related genes and tumor-immune microenvironment characteristics in primary and matched metastatic tissues. We observed a loss of
Identifiants
pubmed: 33096795
pii: cancers12103073
doi: 10.3390/cancers12103073
pmc: PMC7589866
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Cell Death Dis. 2019 Nov 13;10(11):863
pubmed: 31723122
J Cell Physiol. 2018 Apr;233(4):2804-2814
pubmed: 28467642
Nat Rev Mol Cell Biol. 2018 Apr;19(4):245-261
pubmed: 29184195
Pulm Med. 2013;2013:438236
pubmed: 23476762
Clin Cancer Res. 2002 May;8(5):1192-5
pubmed: 12006537
Medicine (Baltimore). 2020 Jan;99(1):e18530
pubmed: 31895788
J Clin Oncol. 2009 Apr 1;27(10):1579-84
pubmed: 19255320
J Cell Biochem. 2009 Feb 1;106(2):210-9
pubmed: 19097084
Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
Nat Genet. 2003 Mar;33(3):357-65
pubmed: 12567188
PLoS One. 2012;7(12):e50141
pubmed: 23251360
Cell Death Dis. 2018 Jul 3;9(7):739
pubmed: 29970892
Rev Physiol Biochem Pharmacol. 2017;173:1-39
pubmed: 28456872
Life Sci. 2018 Apr 1;198:79-86
pubmed: 29462603
Lancet. 2018 May 26;391(10135):2128-2139
pubmed: 29754777
Mol Oncol. 2020 Aug;14(8):1719-1730
pubmed: 32449983
Mol Oncol. 2019 Nov;13(11):2441-2459
pubmed: 31545551
Cancer Lett. 2008 Aug 28;267(2):262-70
pubmed: 18502035
World J Gastroenterol. 2015 Nov 7;21(41):11767-76
pubmed: 26557001
Nat Methods. 2015 Sep;12(9):841-3
pubmed: 26192085
J Clin Oncol. 1995 Jan;13(1):8-10
pubmed: 7799047
Int J Cancer. 2004 Jan 10;108(2):196-9
pubmed: 14639602
Mol Oncol. 2019 Nov;13(11):2361-2374
pubmed: 31350822
Genome Med. 2017 Apr 19;9(1):34
pubmed: 28420421
Mol Oncol. 2019 Dec;13(12):2646-2662
pubmed: 31545548
Genes Dev. 2018 Feb 1;32(3-4):230-243
pubmed: 29463573
Nat Commun. 2018 Nov 14;9(1):4782
pubmed: 30429477
Curr Opin Genet Dev. 2008 Feb;18(1):3-10
pubmed: 18325755
FASEB J. 2010 May;24(5):1347-53
pubmed: 20019240
Nat Commun. 2015 Nov 06;6:8804
pubmed: 26542096
Oncogene. 2004 May 24;23(24):4225-31
pubmed: 15156177
Clin Cancer Res. 2018 Jan 15;24(2):407-419
pubmed: 29074606
Int J Cancer. 2016 Oct 1;139(7):1546-56
pubmed: 27194209
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310
Nat Commun. 2018 Apr 23;9(1):1603
pubmed: 29686383
Artif Cells Nanomed Biotechnol. 2018 Dec;46(8):2082-2087
pubmed: 29268653
Mol Oncol. 2019 Sep;13(9):1827-1835
pubmed: 31322322
Mol Oncol. 2019 Dec;13(12):2697-2714
pubmed: 31600854
Curr Cancer Drug Targets. 2018;18(3):231-238
pubmed: 28359241
J Mol Diagn. 2017 Jan;19(1):4-23
pubmed: 27993330
Hum Pathol. 2017 Jul;65:21-30
pubmed: 28188750
Nat Genet. 2009 Aug;41(8):920-5
pubmed: 19578364
Semin Radiat Oncol. 2006 Apr;16(2):111-9
pubmed: 16564446
Cell Death Dis. 2019 Nov 26;10(12):895
pubmed: 31772156
Nature. 2012 Jul 18;487(7407):330-7
pubmed: 22810696
Oxid Med Cell Longev. 2016;2016:2353560
pubmed: 27433286
Allergy Asthma Clin Immunol. 2016 Aug 11;12:39
pubmed: 27525013
FASEB J. 2014 Oct;28(10):4265-79
pubmed: 24948597
Nat Commun. 2017 Jun 06;8:15180
pubmed: 28585546
Cell Death Dis. 2020 Apr 24;11(4):275
pubmed: 32332709